USPTO Examiner MOORE SUSANNA - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19327881MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOFSeptember 2025January 2026Allow410YesNo
18801407PHARMACEUTICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERSAugust 2024April 2025Allow800YesNo
18673619O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORSMay 2024December 2024Allow610YesNo
18634259NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOFApril 2024March 2025Abandon1120NoNo
18613695SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORSMarch 2024January 2026Allow2220NoNo
18588513METHODS AND COMPOSITIONS FOR MODULATING SPLICINGFebruary 2024September 2025Abandon1910NoNo
18583002LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORSFebruary 2024April 2025Abandon1410NoNo
18545487TRICYCLIC HETEROCYCLES AS FGFR INHIBITORSDecember 2023October 2025Allow2221NoNo
18507678PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODSNovember 2023October 2025Abandon2311NoNo
18507660HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASENovember 2023October 2025Abandon2301NoNo
18387420INHIBITORS OF MENIN-MLL INTERACTIONNovember 2023December 2024Allow1310YesNo
18500786SMALL MOLECULE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) INHIBITORS AND METHODS OF TREATMENTNovember 2023September 2025Allow2221YesNo
18386224BICYCLIC AMINES AS CDK2 INHIBITORSNovember 2023July 2025Allow2011NoNo
18496692SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCEROctober 2023July 2024Allow900NoNo
18488626Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 InhibitorsOctober 2023July 2025Abandon2101NoNo
18487159CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTSOctober 2023December 2024Allow1410YesNo
18476141TOLL LIKE RECEPTOR MODULATOR COMPOUNDSSeptember 2023September 2025Allow2401YesNo
18467162LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORSSeptember 2023November 2023Allow200NoNo
18243068PYRROLO[2,3-C][1,6]NAPHTHYRIDINE-8-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORSSeptember 2023November 2023Allow201YesNo
182413505-SUBSTITUTED PYRIDO[3'',4'':4',5']PYRROLO[3',2':4,5]IMIDAZO[1,2-a]PYRAZINE COMPOUNDS AS CK2 INHIBITORSSeptember 2023November 2023Allow300YesNo
18365286PROTEIN KINASE B INHIBITORSAugust 2023November 2024Allow1511NoNo
18363600PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERSAugust 2023May 2024Allow1011NoNo
18359709SPIRO[BENZO[D]THIAZOLE-6 ,4'- PIPERIDINE AS ACC INHIBITORSJuly 2023March 2026Allow3210YesNo
18351752METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUNDJuly 2023May 2025Allow2211YesNo
18347345SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOFJuly 2023December 2024Allow1810NoNo
18214327LSD DERIVATIVES, SYNTHESIS & METHOD FOR TREATMENT OF DISEASES AND DISORDERSJune 2023November 2024Allow1731YesNo
18267890SYNTHESIS PROCESS OF AMIDE DERIVATIVES OF HYDROXYPENICILLANIC ACIDJune 2023February 2026Allow3201YesNo
18207436CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODSJune 2023August 2025Abandon2611NoNo
18198646PROCESS FOR PREPARING (15ALPHA,16ALPHA,17BETA)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL MONOHYDRATE (ESTETROL MONOHYDRATE)May 2023October 2025Abandon2910NoNo
18196002MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERSMay 2023December 2024Allow1911YesNo
18143720NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOFMay 2023June 2025Allow2511NoNo
18298449DNA Polymerase IIIC Inhibitors and Use ThereofApril 2023September 2025Allow3011NoNo
18124827POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVEMarch 2023March 2024Allow1200YesNo
18185227PYRAZOLE MAGL INHIBITORSMarch 2023December 2024Allow2110NoNo
18120767JAK INHIBITORS AND METHODS FOR SYNTHESIZING AND USING THEREOFMarch 2023November 2025Allow3210YesNo
18245109ANALOGS OF CDDO-2P-IM AND CDDO-3P-IMMarch 2023February 2026Allow3510NoNo
18024612PROCESS FOR PREPARING (3alpha,5alpha)-3-HYDROXY-3-METHYL-PREGNAN-20-ONE (GANAXOLONE)March 2023September 2025Allow3000YesNo
18116094IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORSMarch 2023March 2026Abandon3621NoNo
18176389PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORSFebruary 2023November 2024Abandon2000YesNo
18112699PROCESS FOR THE PREPARATION OF SODIUM (2R,5S,13AR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B] [1,3] OXAZEPIN-8-OLATE AND ITS POLYMORPHIC FORMFebruary 2023May 2024Allow1401YesNo
18171798NEUROACTIVE STEROIDS SUBSTITUTED IN POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERSFebruary 2023March 2026Allow3721NoNo
18041731THERAPEUTIC PHENETHYLAMINE COMPOSITIONS AND METHODS OF USEFebruary 2023August 2024Allow1841YesNo
18020802CRYSTALLINE FORMS OF CFTR MODULATORSFebruary 2023October 2025Allow3200YesNo
18166008BETULASTATIN COMPOUNDSFebruary 2023November 2024Allow2121YesNo
18007421CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFORJanuary 2023February 2026Abandon3710NoNo
18101009GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIAJanuary 2023June 2024Allow1601NoNo
18157783METHODS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERSJanuary 2023September 2023Allow810YesNo
18096392FUSED HETEROAROMATIC PYRROLIDINONESJanuary 2023January 2025Abandon2411NoNo
18089971PRINS REACTION AND COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOFDecember 2022March 2026Abandon3811YesNo
18145901KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOFDecember 2022February 2026Allow3820NoNo
18069646PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USESDecember 2022March 2024Allow1500NoNo
18086397Derivative of berberine, and the preparation method and application thereofDecember 2022November 2024Allow2321YesNo
18083602Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor AntagonistsDecember 2022March 2024Allow1521YesNo
18084208MORPHOLINYLPYRIDONE COMPOUNDSDecember 2022July 2024Abandon1920NoNo
18009481METHYL-SUBSTITUTED BENZOBISOXAZOLE COMPOUND AND USE THEREOFDecember 2022March 2026Allow3920YesNo
18074889GLUCAGON RECEPTOR ANTAGONIST AND USE THEREOFDecember 2022June 2025Allow3000YesNo
18000016MACROCYCLIC JAK INHIBITOR AND USES THEREOFNovember 2022January 2026Abandon3801NoNo
17924792CRYSTALLINE SALT OF ERIBULINNovember 2022June 2025Allow3100YesNo
17983735Heterocyclic Compounds and Uses ThereofNovember 2022November 2025Abandon3620NoYes
17997983FREE BASE CRYSTALSNovember 2022June 2025Allow3100YesNo
17923002NEW MACROCYCLIC LRRK2 KINASE INHIBITORSNovember 2022October 2025Allow3610NoNo
18050650BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USEOctober 2022August 2024Allow2221NoNo
18049344SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOFOctober 2022July 2024Allow2121YesNo
17921278COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF THE RESPIRATORY TRACT INFECTIONSOctober 2022January 2026Abandon3910NoNo
17967508AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORSOctober 2022June 2024Allow2010NoNo
17967483AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORSOctober 2022June 2024Allow2010NoNo
17916727VIRAL ENTRY INHIBITORS AND RNA POLYMERASE INHIBITORSOctober 2022February 2026Abandon4101NoNo
17952460HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORSSeptember 2022May 2025Abandon3111NoNo
17914283NOVEL METHOD FOR PREPARING INOTODIOLSeptember 2022December 2025Abandon3910YesNo
17906884MORPHINAN ISOMERS AND THEIR STRUCTURAL MODIFICATIONS AS NMDAR ANTAGONISTS AND NEUROPLASTOGENSSeptember 2022December 2025Abandon3901NoNo
17933850METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONESeptember 2022January 2023Allow400YesNo
17912301NEUROACTIVE STEROIDS AND THEIR METHODS OF USESeptember 2022March 2026Allow4211NoNo
17932876FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASESeptember 2022July 2023Allow1011NoNo
17910529PURINE COMPOUNDS FOR TREATING DISORDERSSeptember 2022November 2025Allow3810YesNo
17939326ISOTOPICALLY LABELED BILE ACID DERIVATIVESSeptember 2022September 2025Abandon3711NoNo
17902159NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOFSeptember 2022November 2025Abandon3831NoNo
17901007DOPAMINE-B-HYDROXYLASE INHIBITORSSeptember 2022December 2023Abandon1510NoNo
17823254NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRASAugust 2022June 2025Allow3431NoYes
17891869HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORSAugust 2022July 2024Abandon2321NoNo
17887325MATERIAL FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERSAugust 2022December 2022Allow411YesNo
17818873STEROIDS AND METHODS OF MANUFACTUREAugust 2022March 2025Allow3131YesNo
17818517Synthesis Of Benzodiazepine DerivativesAugust 2022September 2025Abandon3840YesNo
17798484POLYMORPHS OF ELAFIBRANORAugust 2022September 2025Allow3701YesNo
17878495ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONSAugust 2022May 2023Allow901YesNo
17759644MACROCYCLIC RIP2-KINASE INHIBITORSJuly 2022January 2026Allow4220NoNo
17874324Novel compounds and their use in therapyJuly 2022January 2024Abandon1811NoNo
17873248NEAR-INFRARED FLUORESCENT INDICATORS FOR LYSOSOME AND APPLICATION THEREOFJuly 2022December 2022Allow500YesNo
17870885SEROTONIN 5-HT2B INHIBITORY COMPOUNDSJuly 2022December 2024Allow2941YesNo
17870156Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa InhibitorsJuly 2022February 2025Abandon3121NoNo
178701515-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa InhibitorsJuly 2022December 2024Allow2921YesNo
17814224HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORSJuly 2022June 2024Abandon2311NoNo
17813805TYK2 INHIBITORS AND USES THEREOFJuly 2022April 2024Abandon2011NoNo
17759054COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOFJuly 2022January 2026Abandon4211YesNo
17864106MAP4K1 INHIBITORSJuly 2022June 2024Allow2321YesNo
17812310TRICYCLIC COMPOUNDS AS INHIBITORS OF KRASJuly 2022December 2025Allow4141YesYes
17810915TRICYCLIC COMPOUNDS AS INHIBITORS OF KRASJuly 2022May 2025Allow3531NoYes
17857149ENVIRONMENTALLY RESPONSIVE TRANS-2-HEXENAL SUSTAINED-RELEASE AGENT, PREPARATION METHOD, AND APPLICATIONJuly 2022October 2025Abandon3931YesNo
17855672THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDSJune 2022October 2023Abandon1601NoNo
17790042PROCESS FOR THE SYNTHESIS OF BUPRENORPHINEJune 2022November 2023Allow1610NoNo
17853647AhR MODULATORSJune 2022November 2024Allow2931NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOORE, SUSANNA.

Strategic Value of Filing an Appeal

Total Appeal Filings
84
Allowed After Appeal Filing
21
(25.0%)
Not Allowed After Appeal Filing
63
(75.0%)
Filing Benefit Percentile
33.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MOORE, SUSANNA - Prosecution Strategy Guide

Executive Summary

Examiner MOORE, SUSANNA works in Art Unit 1624 and has examined 1,593 patent applications in our dataset. With an allowance rate of 66.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner MOORE, SUSANNA's allowance rate of 66.6% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MOORE, SUSANNA receive 1.68 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MOORE, SUSANNA is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +39.2% benefit to allowance rate for applications examined by MOORE, SUSANNA. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.7% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 60.4% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 89.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 56.4% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 13.2% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.